Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Want to see FULC full AI Analyst Report?
FULC Stock Chart & Stats
$8.29
-$0.39(-7.98%)
At close: 4:00 PM EST
$8.29
-$0.39(-7.98%)
Day’s Range― - ―
52-Week Range$2.83 - $15.74
Previous CloseN/A
Volume345.04K
Average Volume (3M)3.23M
Market Cap
$246.54M
Enterprise Value$145.00M
Total Cash (Recent Filing)$333.32M
Total Debt (Recent Filing)$5.87M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 05, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding66,633,320
10 Day Avg. Volume4,348,747
30 Day Avg. Volume3,227,409
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.05
Price to Sales (P/S)0.00
P/FCF Ratio-11.87
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-428.98
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$4.88Price Target Upside-41.19% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-year Cash RunwayA strong cash position with stated runway into 2029 gives Fulcrum multiple quarters to evaluate strategic alternatives or fund development of remaining assets. This financial flexibility reduces immediate financing pressure and supports preservation or monetization efforts over the next 2–6 months.
Dedicated Discovery Capability And Expert Board HireMaintaining an internal discovery team and adding an experienced sickle cell director preserves the company's scientific engine and institutional expertise. This positions Fulcrum to pursue new programs or refine assets for partnering or sale despite clinical setbacks, a durable capability over months.
Active Strategic-review Process With Financial AdviserEngaging a reputable adviser and formally launching a strategic-review creates a structured pathway to realize asset value or secure a transaction. Over the coming months this materially increases the chance of value-maximizing outcomes versus passive asset decline.
Bears Say
Discontinuation Of Lead Program PociredirTerminating the lead sickle cell candidate removes the company's primary path to commercialization and derails the program that drove clinical momentum and investor value. This structural loss forces a fundamental business-model pivot and materially reduces near- to mid-term product prospects.
Severe Workforce Reduction And RestructuringCutting the workforce to a minimal core sharply reduces internal R&D and development capacity, risks loss of institutional knowledge, and limits the company's ability to execute multiple programs or scale operations, impairing medium-term competitiveness and deal execution ability.
Zero Revenue With Persistent Operating Cash BurnSustained zero product revenue combined with repeated operating cash burn creates ongoing funding risk if strategic alternatives fail. Even with current cash, continued losses and no revenue inflow increase the probability of dilution, asset sales, or constrained execution over the next several quarters.
Fulcrum Therapeutics News
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.83 and its highest was $15.74 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $246.54M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 44 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Apr 27, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.044.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Overvalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.23.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 66,633,320 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went down -1.531%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fulcrum Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.88 (-41.19% Downside)
$4.88 (-41.19% Downside)
Blogger Sentiment
Bullish
FULC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 218.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.82%
12-Months-Change
Fundamentals
Return on Equity
-27.80%
Trailing 12-Months
Asset Growth
42.91%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
FULC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical momentum for potociredir — notably a large, rapid increase in HbF, early VOC reduction signals and a clean safety profile — paired with a solid balance sheet and a clear plan for regulatory interactions and a potential registration-enabling trial. Offsetting risks include modestly higher operating losses and expenses, a quarterly cash decline (while runway remains into 2029), delayed availability of meaningful long-term OLE data (likely into 2027), ongoing regulatory uncertainty about surrogate endpoints and emerging competition in the oral HbF inducer space. Overall, the clinical and financial highlights outweigh the operational and regulatory uncertainties.View all FULC earnings summariesFULC Stock 12 Month Forecast
Average Price Target
$4.88
▼(-41.19% Downside)
Technical Analysis
Monopar Therapeutics Inc
―
ADC Therapeutics
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.23% Insiders
8.10% Mutual Funds
58.96% Other Institutional Investors
11.13% Public Companies and
Individual Investors